trimethoprim-sulfamethoxazole + metronidazole — Competitive Intelligence Brief

trimethoprim-sulfamethoxazole + metronidazole (trimethoprim-sulfamethoxazole + metronidazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial dihydrofolate reductase, dihydropteroate synthase, and anaerobic DNA Infectious Disease Small molecule

Target snapshot

trimethoprim-sulfamethoxazole + metronidazole (trimethoprim-sulfamethoxazole + metronidazole) — Halmstad County Hospital. This combination uses two antibiotics with different mechanisms—trimethoprim-sulfamethoxazole inhibits bacterial folate synthesis, while metronidazole disrupts DNA in anaerobic organisms—to provide broad-spectrum coverage against aerobic and anaerobic bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
trimethoprim-sulfamethoxazole + metronidazole TARGET	trimethoprim-sulfamethoxazole + metronidazole	Halmstad County Hospital	marketed	Antibiotic combination	Bacterial dihydrofolate reductase, dihydropteroate synthase, and anaerobic DNA
Different Antibiotic Combinations	Different Antibiotic Combinations	Inonu University	marketed	Antibiotic combinations	Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication
BENZOYL PEROXIDE/ CLINDAMYCIN	BENZOYL PEROXIDE/ CLINDAMYCIN	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Vonoprazan + amoxicillin	Vonoprazan + amoxicillin	The Third Xiangya Hospital of Central South University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Acnatac® Gel left face	Acnatac® Gel left face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Trimethoprim and sulfamethoxazole	Trimethoprim and sulfamethoxazole	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class